Gastroparesis
Atmo capsule may offer ‘potential replacement’ for nixed SmartPill in motility disorders
PHILADELPHIA — An ingestible gas-sensing capsule from Atmo Biosciences showed “substantial agreement” with the discontinued Medtronic wireless motility device for measuring regional transit times in gastrointestinal motility disorders.
Vanda’s tradipitant falls short for gastroparesis as FDA requests ‘additional studies’
The FDA has issued a complete response letter to Vanda Pharmaceuticals indicating it cannot approve the company’s new drug application seeking approval for tradipitant as a treatment for gastroparesis.
Gastroparesis Awareness Month empowers patients to share their stories, make a #GPimpact
Every August, gastrointestinal care providers and patient advocacy groups celebrate Gastroparesis Awareness Month, an annual campaign focused on improving understanding of gastroparesis and promoting preventive strategies.
Q&A: Endometriosis impact on GI function remains ‘vastly understudied, underrecognized’
Women with endometriosis had higher rates of health care utilization and were significantly more likely to experience upper gastrointestinal and dyspeptic symptoms, according to preliminary data in Clinical Gastroenterology and Hepatology.
Tradipitant achieves ‘clinically meaningful outcomes’ in gastroparesis
Although neurokinin-1 receptor antagonist tradipitant did not outperform placebo in improving nausea severity at 12 weeks in patients with gastroparesis, those with adequate tradipitant exposure did achieve overall symptom improvement.
Vagal nerve stimulation reduces need for rescue medication in gastroparesis, dyspepsia
VANCOUVER, British Columbia — As-needed vagal nerve stimulation reduced rescue mediation use among patients with nausea related to gastroparesis or functional dyspepsia, according to data presented at the ACG Annual Scientific Meeting.
FDA grants MR conditional use to Enterra’s electrical stimulation device for gastroparesis
The FDA has granted conditional use with magnetic resonance imaging to Enterra Medical’s implantable electrical stimulation device for management of symptoms associated with gastroparesis, according to a company release.
New data links GLP-1 agonists for weight loss with higher risk for pancreatitis, GI events
Use of glucagon-like peptide 1 agonists for weight loss compared with bupropion-naltrexone was associated with an increased risk for pancreatitis, gastroparesis and bowel obstruction but not biliary disease, researchers reported in JAMA.
‘No need for alarm,’ despite associations between certain GI conditions and Parkinson’s
Case-control and cohort analyses showed dysphasia, gastroparesis, irritable bowel syndrome without diarrhea and constipation may be associated with an increased risk for Parkinson’s disease, according to research in Gut.
Q&A: Gastroparesis from Ozempic, Wegovy 'uncommon'
Recent reports in the media and legal action have raised questions about the safety of popular weight-loss drugs, particularly about whether they increase the risk for events such as gastroparesis and gastroenteritis.